Advocate, AZ: Ep. 64 Dr Sue Sisley скачать в хорошем качестве

Advocate, AZ: Ep. 64 Dr Sue Sisley

http://cecono.me twitter.com/canneconomy facebook.com/canneconomy Dr. Sue Sisley’s name first popped up in headlines last year when news broke that she had been fired from the University of Arizona, shortly after getting a study approved to examine the use of marijuana to treat PTSD in war veterans. While the University has denied the decision had anything to do with the nature of Dr. Sisley’s research, many have chalked it up to another attempt to stifle the cannabis movement, and support for Dr. Sisley arose nationwide. In this interview, she tells us about everything she’s doing to ensure that her research can be conducted and proliferated for the benefit of science, and for the benefit of veterans worldwide. She breaks down some of her scientific reasoning, as well as detailing the many different forms of political opposition that has been standing in her way. The effects of PTSD are, in her words, one of the biggest public health crises facing America right now, and we are all glad that Dr. Sisley is doing all she can on behalf of these veterans and of the plant. Enjoy! “Every human body has an endocannabinoid system. That was discovered in the 80s and further elucidated in the 90s, and yet no medical schools to date teach this material, and that’s very sad” “We need to trust patients to treat themselves, and patients [have already] been proving for so many years now that they know how to do that.” “We just had a poll that came out from a very reputable national polling agency… [asking] ‘do you support marijuana research for veterans with PTSD?’ and 83% said yes. So there’s no doubt that these elected officials do not represent the public.” “The plant has massive potential to reduce human suffering, and the fact that it is being forced to sit on the shelf, that it’s being vilified unfairly, is just sickening to me.” “I think the barriers to research have been the most shocking to me, the fact that this is the least toxic of all the drugs in Schedule 1, and yet it has the most onerous barriers when it comes to studying efficacy.”